The largest multi-centre study to date of hepatitis from immune checkpoint inhibitor therapy reveals the side effect leads to significant rates of early treatment disruption, permanent discontinuation, and even death. Patients who develop the condition require high-dose steroids, and second-line immunosuppression and ICI therapy re-challenge in this group is associated with a ‘modest rate’ of ...
Vigilance needed for checkpoint inhibitor-induced hepatitis
By Sunalie Silva
10 Mar 2021